The Relationship Between Chemotherapy-Induced Peripheral Neuropathy and Underlying Inflammatory Skin Disorders

Authors: Teja Mallela, BS; Lily Kaufman, BS; Brittany Dulmage, MD **Affiliations:** The Ohio State College of Medicine, Department of Dermatology

BACKGROUND

- Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse conditions due to chemotherapy¹.
- The development of CIPN can lead to patients being unable to tolerate chemotherapy and subsequent discontinuation^{2,6}.
- Current literature has established cytokine-driven interactions between skin and neuronal cells that occur during inflammatory skin disease².
- Grace Shin Lab at Ohio State:
- Paclitaxel, a common chemotherapy drug, affects keratinocytes: Reduced cell junctions at desmosomes
- Increased DNA damage
- Decreased proliferation
- This nerve-skin relationship could explain the predisposition to developing CIPN in patients with existing skin diseases receiving chemotherapy.

STUDY AIMS

- This study investigates the incidence of CIPN among patients who underwent chemotherapy with and without an underlying skin disease.
- Additionally, we determine whether the development of CIPN is associated with increased rates of hand-foot syndrome (HFS).

METHODS

- The primary data source for this study was the Ohio State Information Warehouse.
- Inclusion criteria included:
- Age of 18 or older, diagnosed with cancer, completed chemotherapy between May 2010 and May 2023
- Data collected:
- Age at the time of cancer diagnosis, sex, race, ethnicity
- Information regarding dermatologic conditions, cancer diagnoses, chemotherapy regimens, and side effects from chemotherapy
- Statistical analysis: Multinomial logistic regression was used to assess variables of interest. Statistical significance was set at p-value < 0.05.

TABLE 1. Cohort Demographics an Female Sex Male Other Race Race Black White Age at Chemo Initiation Mean (SD) CIPN Yes No HFS Yes iDerm Dx Before Inflammatory Derm Dx Timing iDerm Dx After (Relative to Cancer Dx date) No iDerm Dx Total 100% 90% 80% 70% 60% 86.2% 88.0% 93.2% 50% 40% 30% 20% 10% 13.8% 12.0% 6.8% 0% Male Other Race Female Sex CONCLUSION Patients who develop CIPN are more likely to be female and less likely to be Black. CIPN patients are more likely to be diagnosed with a dermatological condition after their cancer diagnosis. • This could imply **increased surveillance or late-onset skin toxicity** following chemotherapy. CIPN patients are more likely to develop HFS as well when compared to cancer patients without CIPN. • This suggests a strong relationship between these two chemotherapy toxicities, possibly due to shared

pathological mechanisms or treatment regimens.

RESULTS & DISCUSSION

and Rates of CIPN and HFS	5	Demogra
Ν	Percentage	• Fem
8126	53.0%	(OR
7204	47.0%	• Blac
550	3.6%	Whit
1802	11.8%	
12978	84.7%	• Age 0.99
61.4 (11.5)	_	0.99
1615	10.5%	
13715	89.5%	Role of D
69	0.5%	• A de
15261	99.5%	mod
1273	8.3%	
664	4.3%	Interdep
13393	87.4%	Patie
15330	100.0%	dev

Figure 1. Presence of CIPN by Patient Characteristics

		71.0%					
91.0%	89.3%			89.5%			
		29.0%					
9.0%	10.7%			10.5%			
Black	White	HFS		No HFS		iC	
Race		HFS Status					

- Pract. 2012;2012:913848.



THE OHIO STATE

UNIVERSITY

COLLEGE OF MEDICINE

raphic Factors

male sex is significantly associated with higher odds of CIPN R = 2.16, p-value < 0.001).

ack patients had lower odds of developing CIPN compared to nite patients (OR = 0.84, p-value = 0.04).


e: Slightly protective against CIPN with increasing age (OR = 9, p-value = 0.007).

Dermatologic Conditions

dermatological diagnosis after chemotherapy initiation is destly associated with **CIPN** (OR = 1.36, p-value 0.01).

pendence between CIPN and HFS

tients with CIPN had a significantly higher likelihood of developing HFS (OR = 2.77, p-value = 0.002).



REFERENCES

1. Sherry Wolf, Debra Barton, Lisa Kottschade, Axel Grothey, Charles Loprinzi. Chemotherapy-induced peripheral neuropathy: Prevention and treatment strategies. European Journal of Cancer, Volume 44, Issue 11, 2008, Pages 1507-1515, ISSN 0959-8049 2.Zaiem, A., Hammamia, S. B., Aouinti, I., Charfi, O., Ladhari, W., Kastalli, S., Aidli, S. E., & Lakhoua, G. (2022). Hand-foot syndrome induced by chemotherapy drug: Case series study and literature review. Indian journal of pharmacology, 54(3), 208–215. 3.Kwatra, S. G., Misery, L., Clibborn, C., & Steinhoff, M. (2022). Molecular and cellular mechanisms of itch and pain in atopic dermatitis and implications for novel therapeutics. Clinical & translational immunology, 11(5), e1390.

4.Kolb NA, Smith AG, Singleton JR, Beck SL, Stoddard GJ, Brown S, Mooney K (2016) The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling. JAMA Neurol 73:860-866. 5. Pike CT, Birnbaum HG, Muehlenbein CE, Pohl GM, Natale RB. Healthcare costs and workloss burden of patients with

chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and non small cell lung cancer. Chemother Res

6. Winters-Stone KM, Horak F, Jacobs PG, Trubowitz P, Dieckmann NF, Stoyles S, Faithfull S (2017) Falls, functioning, and disability among women with persistent symptoms of chemotherapy-induced peripheral neuropathy. J Clin Oncol 35:2604–2612.